On June 4, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that the Company has received a positive decision from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC(the "Staff"), granting the Company’s request for an extension through October 5, 2020 to achieve compliance with the minimum $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (Press release, AEterna Zentaris, JUN 4, 2020, View Source [SID1234560860]). The Staff’s determination followed the Company’s submission of its compliance plan for the Staff’s consideration on May 26, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is pursuing a number of initiatives to increase stockholders’ equity, the completion of which are expected to enable it to achieve compliance with the minimum stockholders’ equity requirement by no later than October 5, 2020 and to thereafter maintain compliance with the listing requirements.